The estimated $30 million investment will build upon the site’s existing development and manufacturing capabilities and will address the growing demand for strong US-based capacity for ADCs and other potent small molecules, the company said.

The expansion will include a new high potent process development laboratory and two new cGMP suites designed to handle potent compounds with occupational exposure limits (OEL) of less than 0.01 µg/m³. The new facilities will be equipped to handle high potency compounds, ADC linker-payloads, and other complex molecules.

“At Veranova, we recognize the growing demand for development and manufacturing of ADCs and other highly potent compounds,” said Mike Riley, CEO of Veranova. “This investment signals our commitment to providing state of the art capacity and capabilities to enable these next generation therapies to reach patients, and is a key milestone as we advance our broader growth strategy for Veranova.”

Veranova's site in Devens, near the pharmaceutical and biotech hub of Boston, is an FDA-approved facility that can conduct development, clinical manufacturing and commercial production under one roof.